Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 16Unknown 3Recruiting 3Terminated 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 35Breast Neoplasms 27Prostatic Neoplasms 22Stomach Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Neoplasms 10Lung Neoplasms 10Urinary Bladder Neoplasms 8Head and Neck Neoplasms 8Triple Negative Breast Neoplasms 7Neoplasm Metastasis 7Carcinoma, Squamous Cell 6Non-Muscle Invasive Bladder Neoplasms 5Nasopharyngeal Carcinoma 5Carcinoma, Transitional Cell 5Adenocarcinoma 5Oropharyngeal Neoplasms 4Sarcoma 3Prostatic Neoplasms, Castration-Resistant 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3HER2-positive Breast Cancer 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Vaccinia 2Recurrence 2Peritoneal Neoplasms 2Metastatic Castration-Resistant Prostate Cancer 2

Interventions

Cisplatin 20Radiotherapy 16Paclitaxel 14Carboplatin 12pembrolizumab 11Drug Therapy 11tislelizumab 10Fluorouracil 8Neoadjuvant Therapy 7130-nm albumin-bound paclitaxel 7sintilimab 5Esophagectomy 5toripalimab 4Tegafur 4TP protocol 4Nivolumab 4Irinotecan 4Immunotherapy 4spartalizumab 3S 1 (combination) 3Oxaliplatin 3Leucovorin 3Itraconazole 3Docetaxel 3Albumin-Bound Paclitaxel 3nimotuzumab 2apatinib 2Taxes 2Radiotherapy, Intensity-Modulated 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Esophageal Squamous Cell Carcinoma × Docetaxel × Clear all
NCT07463573 2026-04-24

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
466 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06644781 2026-01-12

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Daiichi Sankyo

Phase 3 Recruiting
510 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06194734 2024-03-07

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

Beijing Konruns Pharmaceutical Co., Ltd.

Phase 3 Recruiting
490 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡